2248046-39-9
Chemical Structure
FCN-338
Synonym(s): LOXO-338
- CAS No.: 2248046-39-9
- Formula:C48H48ClN7O7S
- Molecular Weight:902.46
SMILES: ClC1=CC=C(C=C1)C(CC(C)(CC2)C)=C2CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(OC6)=C(C([N+]([O-])=O)=C5)N[C@H]6CC7=CC=CC=C7)=O)=O)C(OC8=CN=C9NC=CC9=C8)=C4)CC3
Biological Activity: FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FCN-338 | 99.33% | FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Brandhuber B, et al. Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor[J]. Cancer Research, 2021, 81(13_Supplement): 1258-1258.
- [2]. Vogler M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025 Mar 21;10(1):91. [Content Brief]
